Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) Overview
- Year Founded
-
2013
- Status
-
Private
- Latest Deal Type
-
Joint Venture
- Financing Rounds
-
1
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) General Information
Description
Developer of drugs for the treatment of viral hemorrhagic fever viruses. The joint venture is focused on monoclonal antibody (mAb) drugs for the treatment of viral hemorrhagic fever viruses e.g. Ebola or Marburg viruses.
Contact Information
Corporate Office
- United States
Corporate Office
- United States
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) FAQs
-
When was Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) founded?
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) was founded in 2013.
-
Where is Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) headquartered?
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) is headquartered in .
-
What industry is Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) in?
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical)’s primary industry is Buildings and Property.
-
Is Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) a private or public company?
Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) is a Private company.
-
What is Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical)’s current revenue?
The current revenue for Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical) is .
-
Who are Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical)’s investors?
Defyrus and Mapp Biopharmaceutical have invested in Monoclonal Antibody Drugs for Hemorrhagic Fever Viruses (Defyrus / Mapp Biopharmaceutical).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process